3-chloro-4-propoxybenzonitrile | 1216124-05-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-chloro-4-propoxybenzonitrile
• CAS: 1216124-05-8
• 化学式: C₁₀H₁₀ClNO
• mdl: MFCD14537007
• 分子量: 195.648
• InChiKey: IYUPNWQVPPDJMQ-UHFFFAOYSA-N

物化性质

• 沸点：
  295.8±20.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-chloro-4-propoxybenzonitrile 在 aluminum (III) chloride 、 lithium aluminium tetrahydride 、 盐酸 作用下， 以 乙醚 为溶剂， 反应 19.5h， 以61%的产率得到(3-chloro-4-propoxyphenyl)methanaminium chloride
  参考文献：
  名称：

  Novel non-ATP competitive small molecules targeting the CK2 α/β interface

  摘要：

  Increased CK2 levels are prevalent in many cancers. Combined with the critical role CK2 plays in many cell-signaling pathways, this makes it a prime target for down regulation to fight tumour growth. Herein, we report a fragment-based approach to inhibiting the interaction between CK2 alpha and CK2 beta at the alpha-beta interface of the holoenzyme. A fragment, CAM187, with an IC50 of 44 mu M and a molecular weight of only 257 gmol(-1) has been identified as the most promising compound. Importantly, the lead fragment only bound at the interface and was not observed in the ATP binding site of the protein when co-crystallised with CK2 alpha. The fragment-like molecules discovered in this study represent unique scaffolds to CK2 inhibition and leave room for further optimisation.

  DOI：

  10.1016/j.bmc.2018.05.011
• 作为产物：
  描述：

  C₁₁H₁₄ClNO₂ 在 [RuCl2(p-cymene)]2 、 二苯基乙炔 作用下， 以 异丙醇 为溶剂， 反应 16.0h， 以92%的产率得到3-chloro-4-propoxybenzonitrile
  参考文献：
  名称：

  钌催化的O-甲基苯并氧肟基卤化物的分子内选择性卤化：卤代芳族腈的新途径。

  摘要：

  在Ru催化剂和配体二苯乙炔的存在下，O-甲基苯并氧肟基卤化物的分子内卤化以高度区域选择性的方式提供了卤素取代的芳族腈。此外，在NaN 3和I 2的存在下，取代的腈被转化为取代的四唑衍生物。

  DOI：

  10.1039/c3cc41124a

文献信息

• [EN] CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES<br/>[FR] DÉRIVÉS CARBOXY PRÉSENTANT DES PROPRIÉTÉS ANTI-INFLAMMATOIRES
  申请人：SITRYX THERAPEUTICS LTD

  公开号：WO2021130492A1

  公开（公告）日：2021-07-01

  The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein, RA1, RA2, RC and RD are as defined herein.

  这项发明涉及式(I)的化合物及其在治疗或预防炎症性疾病或与不良免疫反应相关的疾病中的应用：(I)其中，RA1、RA2、RC和RD如本文所定义。
• A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066
  作者：Claudia De Fusco、Paul Brear、Jessica Iegre、Kathy Hadje Georgiou、Hannah F. Sore、Marko Hyvönen、David R. Spring

  DOI：10.1016/j.bmc.2017.04.037

  日期：2017.7

  Recently we reported the discovery of a potent and selective CK2 alpha inhibitor CAM4066. This compound inhibits CK2 activity by exploiting a pocket located outside the ATP binding site (alpha D pocket). Here we describe in detail the journey that led to the discovery of CAM4066 using the challenging fragment linking strategy. Specifically, we aimed to develop inhibitors by linking a high-affinity fragment anchored in the alD site to a weakly binding warhead fragment occupying the ATP site. Moreover, we describe the remarkable impact that molecular modelling had on the development of this novel chemical tool. The work described herein shows potential for the development of a novel class of CK2 inhibitors. (C) 2017 Published by Elsevier Ltd.